Sekisui Chemical Vision 2030: Perovskite Solar Cells and Life Sciences Drive 2 Trillion Yen Growth Strategy
Date : 2026-02-05
Reading : 97
According to the latest comprehensive analysis by HDIN Research, Sekisui Chemical is aggressively executing its "Vision 2030" long-term roadmap. The company aims to double its business scale to 2 trillion JPY in sales and achieve an operating profit margin exceeding 10% by fiscal year 2030. This transformation is anchored in a strategic shift toward seven specific "Innovation Domains," ranging from next-generation energy solutions to advanced medical technologies.
HDIN Research highlights that Sekisui Chemical is leveraging its proprietary Technology Platform (TPF) combined with a 300 billion JPY investment budget for M&A and corporate venture capital. This capital allocation is designed to accelerate the commercialization of technologies that address global social issues, particularly carbon neutrality and aging infrastructure.
Figure Sekisui Chemical Strategic Trajectory Toward Vision 2030
The Crown Jewel: Perovskite Solar Cells (PSC)
The central pillar of Sekisui Chemical's innovation strategy is the commercialization of film-type Perovskite Solar Cells. Unlike traditional silicon-based panels, these cells are lightweight (approximately one-tenth the weight) and flexible, allowing installation on low-load roofs, building facades, and curved surfaces previously unsuitable for solar power.
HDIN Research notes the following milestones in the PSC roadmap:
Capacity Expansion: A 100MW production line is scheduled to launch at the Sakai Plant by April 2027, with a goal to reach GW-scale capacity by 2030.
Financial Targets: The company projects this business to generate between 150 billion and 200 billion JPY in revenue by 2030.
Technical Goals: Sekisui is pursuing the "Triple 20" target: 20% efficiency, 20-year durability, and a generation cost of 20 JPY/kWh.
Strategic Diversification: Life Sciences and Infrastructure
Beyond energy, Sekisui Chemical is restructuring its portfolio to establish Life Science as its fourth core business pillar alongside High Performance Plastics, Housing, and Urban Infrastructure.
In the Life Science domain, the company is transitioning from basic contract manufacturing to a high-value Contract Development and Manufacturing Organization (CDMO) model. This expansion focuses on new modalities, such as regenerative medicine and gene therapy, supported by strategic acquisitions.
In the Infrastructure domain, the focus remains on global expansion. The company is capitalizing on the urgent need to rehabilitate aging sewage pipelines in developed markets using its trenchless SPR technology. Additionally, the export of synthetic railway sleepers (FFU), which replace wooden sleepers, is gaining traction in Europe due to environmental regulations.
ESG as a Financial Driver
HDIN Research observes that Sekisui Chemical has successfully integrated ESG goals with financial performance. The company uses a "Sustainability Contribution Products" (SCP) classification to track revenue quality. In FY2024, SCPs accounted for 76.8% of total sales.
The company has secured Science Based Targets (SBT) certification for a 1.5 degree Celsius pathway. A key initiative includes "Biorefinery" technology, developed in partnership with LanzaTech, which converts unsorted municipal waste into ethanol. This technology is expected to reach commercial scale by 2028, creating a circular economy model that contributes to both carbon reduction and raw material security.
Summary of Key Innovation Domains and 2030 Targets
The following table summarizes the strategic focus areas identified by HDIN Research in Sekisui Chemical's long-term plan:
Analyst Conclusion
HDIN Research concludes that Sekisui Chemical is effectively transitioning from a traditional processing manufacturer to a social-solution provider. The firm's high equity ratio (over 60%) and strong cash flow generation provide the necessary resilience to fund high-risk, high-reward projects like Perovskite Solar Cells. Investors and corporate partners should closely monitor the yield rates of the new PSC production line in 2027, as this will be a definitive indicator of the company's ability to achieve its 2 trillion JPY vision.
About HDIN Research
Profile: HDIN Research focuses on providing market consulting services. As an independent third-party consulting firm, it is committed to providing in-depth market research and analysis reports.
Website: www.hdinresearch.com
E-mail: sales@hdinresearch.com
HDIN Research highlights that Sekisui Chemical is leveraging its proprietary Technology Platform (TPF) combined with a 300 billion JPY investment budget for M&A and corporate venture capital. This capital allocation is designed to accelerate the commercialization of technologies that address global social issues, particularly carbon neutrality and aging infrastructure.
Figure Sekisui Chemical Strategic Trajectory Toward Vision 2030
The Crown Jewel: Perovskite Solar Cells (PSC)The central pillar of Sekisui Chemical's innovation strategy is the commercialization of film-type Perovskite Solar Cells. Unlike traditional silicon-based panels, these cells are lightweight (approximately one-tenth the weight) and flexible, allowing installation on low-load roofs, building facades, and curved surfaces previously unsuitable for solar power.
HDIN Research notes the following milestones in the PSC roadmap:
Capacity Expansion: A 100MW production line is scheduled to launch at the Sakai Plant by April 2027, with a goal to reach GW-scale capacity by 2030.
Financial Targets: The company projects this business to generate between 150 billion and 200 billion JPY in revenue by 2030.
Technical Goals: Sekisui is pursuing the "Triple 20" target: 20% efficiency, 20-year durability, and a generation cost of 20 JPY/kWh.
Strategic Diversification: Life Sciences and Infrastructure
Beyond energy, Sekisui Chemical is restructuring its portfolio to establish Life Science as its fourth core business pillar alongside High Performance Plastics, Housing, and Urban Infrastructure.
In the Life Science domain, the company is transitioning from basic contract manufacturing to a high-value Contract Development and Manufacturing Organization (CDMO) model. This expansion focuses on new modalities, such as regenerative medicine and gene therapy, supported by strategic acquisitions.
In the Infrastructure domain, the focus remains on global expansion. The company is capitalizing on the urgent need to rehabilitate aging sewage pipelines in developed markets using its trenchless SPR technology. Additionally, the export of synthetic railway sleepers (FFU), which replace wooden sleepers, is gaining traction in Europe due to environmental regulations.
ESG as a Financial Driver
HDIN Research observes that Sekisui Chemical has successfully integrated ESG goals with financial performance. The company uses a "Sustainability Contribution Products" (SCP) classification to track revenue quality. In FY2024, SCPs accounted for 76.8% of total sales.
The company has secured Science Based Targets (SBT) certification for a 1.5 degree Celsius pathway. A key initiative includes "Biorefinery" technology, developed in partnership with LanzaTech, which converts unsorted municipal waste into ethanol. This technology is expected to reach commercial scale by 2028, creating a circular economy model that contributes to both carbon reduction and raw material security.
Summary of Key Innovation Domains and 2030 Targets
The following table summarizes the strategic focus areas identified by HDIN Research in Sekisui Chemical's long-term plan:
| Innovation Theme | Key Technology / Application | Commercialization & Financial Goals |
|---|---|---|
| Perovskite Solar Cells (PSC) | Lightweight flexible film solar for buildings and mobility | GW-scale production by 2030; Revenue target: 150-200 billion JPY |
| Biorefinery | Converting municipal waste to ethanol via microbial technology | Commercial plant operation by approx. 2028; establishing circular carbon resources |
| Medical CDMO | Contract development for new modalities (gene therapy/regenerative) | Establishment as the 4th business pillar; Aggressive M&A strategy to expand footprint |
| Smart City & Housing | Data-driven town management and ZEH (Net Zero Energy House) | Revenue target of 25 billion JPY by FY2025; Focus on resilience and health |
| Air Mobility | High-value composite materials for aircraft and flying vehicles | Revenue target of 19 billion JPY by FY2025 |
| Next-Gen Communications | Transparent flexible radio wave reflection films for 5G/6G | Improving connectivity environments in urban spaces |
| Overseas Infrastructure | Synthetic railway sleepers (FFU) and pipeline rehabilitation | Global expansion to address aging infrastructure in Europe and the US |
HDIN Research concludes that Sekisui Chemical is effectively transitioning from a traditional processing manufacturer to a social-solution provider. The firm's high equity ratio (over 60%) and strong cash flow generation provide the necessary resilience to fund high-risk, high-reward projects like Perovskite Solar Cells. Investors and corporate partners should closely monitor the yield rates of the new PSC production line in 2027, as this will be a definitive indicator of the company's ability to achieve its 2 trillion JPY vision.
About HDIN Research
Profile: HDIN Research focuses on providing market consulting services. As an independent third-party consulting firm, it is committed to providing in-depth market research and analysis reports.
Website: www.hdinresearch.com
E-mail: sales@hdinresearch.com